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Available online 20 June 2016Malignant pleural mesothelioma (MPM) is a tumor originating in the mesothelium, the membrane lining the
thoracic cavities, and is induced by exposure to asbestos. Australia suffers one of the world's highest rates of
MPMand the incidence is yet to peak. The prognosis for patientswithMPM is poor andmedian survival following
diagnosis is 4–18months. Currently, no or few effective therapies exist for MPM. Trials of targeted agents such as
antiangiogenic agents (VEGF, EGFR) or ribonuclease inhibitors (ranpirnase) largely failed to show efﬁcacy in
MPM Tsao et al. (2009) [1]. A recent study, however, showed that cisplatin/pemetrexed + bevacizumab (a re-
combinant humanized monoclonal antibody that inhibit VEGF) treatment has a survival beneﬁt of 2.7 months
Zalcman et al. (2016) [2]. It remains to be seen if this targeted therapy will be accepted as a new standard for
MPM. Thus the unmet needs of MPM patients remain very pronounced and almost every patient will be
confrontedwith drug resistance and recurrence of disease.We have identiﬁed unique gene signatures associated
with prolonged survival in mesothelioma patients undergoing radical surgery (EPP, extrapleural pneumonecto-
my), as well as patients who underwent palliative surgery (pleurectomy/decortication). In addition to data pub-
lished in Molecular Oncology, 2015;9:715-26 (GSE59180) Kirschner et al. (2015) , we describe here additional
data using a system-based approach that support our previous observations. This data provides a resource to
further explore microRNA dynamics in MPM.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
microRNA
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Systems biology
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Speciﬁcationsrganism/cell line/tissue Human malignant mesothelioma tissue
(micro-dissected using laser capture)x Male 75%, female 25% (2 females in long and short
group respectively)quencer or array type Agilent unrestricted AMADID miRNA
8x15k-AMADID:021827 miRNA arrayata format Log2 transformation and normalized to the 90th
percentile without baseline transformation.xperimental factors Short-term vs long-term survival, without prior
chemotherapyxperimental features Differential gene expression of microRNAs were
selected and evaluated against clinical data of survival
outcome to determine their prognostic nature.onsent Waiver of consent for these patient samples was granted
by the Human Research Ethics Committee at Concord
Repatriation General Hospital, Sydney, AustraliaInstitute, Sydney, Australia.
. This is an open access article under thcontinued)
Speciﬁcationse CC BY license (http://crea(CH62/6/2009/078). The histopathology of all samples
was independently reassessed by Assoc Prof Sonja Klebe,
an expert pathologist and ﬁnal diagnoses were made
according to World Health Organization criteria [4].mple source location Sydney, AustraliaSa1. Direct link to deposited data
MicroRNA proﬁling of malignant pleural mesothelioma tumour tis-
sues, http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE59180
2. Experimental design, materials and methods
The experimental design and analysis pipeline are outlined in Fig. 1.
Brieﬂy, we used 16 FFPE (formalin-ﬁxed parafﬁn embedded)
tumor samples from patients who underwent EPP (extrapleuraltivecommons.org/licenses/by/4.0/).
Fig. 1.Analysis pipelines for miR-Score (Kirschner et al. [3]) and additional bioinformatics analysis. *This P/D cohort consisted of 75 patients but only 43 passed the criteria for RNA quality
and quantity to be put forward for microRNA validation experiment.
45R.C.Y. Lin et al. / Genomics Data 9 (2016) 44–49pneumonectomy) [3,5] to interrogate the prognostic value of genome-
wide microRNA gene expression. The RNA samples were divided into
2 groups; 1) long survival, median = 53.7 months, n = 8 and 2) short
survival, median = 6.4 months, n = 8. Agilent Human 8x15k miRNA
microarrays (GPL10850) were utilized for microRNA transcriptome
proﬁling. Agilent feature extraction v10.5 was used to extract ﬂuores-
cence intensity.
2.1. Data processing
Total Gene Signals from themiRNA arrays were quantile normalized
and log transformed to base 2. Further ﬁltering was applied to exclude
ones with gene expression of b1 (Partek Genome Suite, v6.6). In com-
parison, Kirschner et al., 2015 used signal value of 1 as a threshold and
normalized by shifting to the 90th percentile without applying baseline
transformation. The intention here is to show that regardless of normal-
izationmethods used for the initial array data processing (Fig. 1), candi-
date microRNAs identiﬁed still hold true their association with the
phenotype and in particular, the affected regulatory pathways where
predicted genes are targeted by these microRNAs.
One-way ANOVA was used to examine differential gene expression
between long and short survival (n= 16 in total). This analysis also as-
sumes that long and short survival-related gene expression patterns are
normally distributed and that the variance is approximately equal be-
tween the groups. Conﬁguring the ANOVA in Partek Genome Suite
(v6.6) enabled adjustment for systematic technical errors, such as
batch processing of the RNA samples as well as the shortcomings of
RNA extraction from FFPE blocks.
2.2. Visualization of gene expression and regulatory pathways
To visualize the dataset, further analysis was carried out to identify
distinctive gene expression patterns using Self-Organizing Map (SOM)
clustering (map height= 4,mapwidth=3) (Fig. 2A). Cluster structure
of this dataset in the form of non-linear mapping to a two-dimensionalgrid (SOM clustering) enabled us to explore the relationship and
ultimately the function of these microRNAs. Hierarchical clustering
(Fig. 2B) was also utilized (subdivide gene expression in similar vs dif-
ferent clusters) to identify signiﬁcantly enriched functional categories.
This is useful for unknown genes in the same cluster to enable us to
infer a functional role. Two distinctive SOM clusters were identiﬁed
and assigned to “Long Survival” and “Short Survival” based on the fol-
lowing criteria; 1) P b 0.05 differentially expressed, 2) Fold change
N1.5 and 3) correlation with enriched pathway based on predicted tar-
gets. We focused on 2 clusters, cluster 1 and cluster 11, as they showed
distinct expression differences between long and short survival (Fig. 2A,
Table 1).
Predicted target genes of microRNAs in the “Long Survival” and
“Short Survival” clusters were extracted from miRDB [6] (Version 6.0,
release date: August 2014) and starBase Version 2.0 [7]. Within
starBase, predicted targets were extracted based on intersections with
TargetScan [8], picTar [9], RNA22 [10], PITA [11] and miRanda/mirSVR
[12]. This resolves some of the issues surrounding use of predicted tar-
gets from bioinformatics approaches where validation of targets leads
to an estimated false positive rate of at least 20–40% [13,14] and false
negative rates of up to 50% [15,16]. Although protocols such as HITS-
CLIP [17] or PAR-CLIP [18] are considered in starBase for determining
RISC occupancy onmicroRNAs, similar pitfalls still exist andwe proceed
with caution. The parameters used for starBase are medium stringency
(≥2CLIP-Seq experiments supported the predicted miRNA target site).
To interrogate the data further, gene ontology (GO) enrichment
analysis based on these target gene lists (Fisher's Exact test) was carried
out to detect over-represented genes and to reﬂect enriched biological
themes (biological process, molecular function and cellular component)
as described [3]. Pathway enrichment analysis was carried out on this
predicted target gene list to explore association of enriched regulatory
pathways with patient survival outcome. This is based on Fisher's
Exact test (P b 0.05), using the KEGG (Kyoto Encyclopedia of Genes
and Genomes) [19] Homo sapiens hg19 Build reference genome as the
background [3] as well as hg38 Build (Fig. 1). The aim was to
Fig. 2. Visualization of microRNA microarray data. (A) SOM clustering of distinctive microRNA gene expression patterns in long vs short survival patients. (B) Hierarchical clustering
showed distinctive gene expression pattern of candidate microRNAs to reﬂect coordinated regulation in long vs short survival patients.
Table 1
Long survival microRNAs vs short survival microRNAs by SOM clustering analysis.
Cluster 1: short survival microRNA p-Value (short vs long) Fold-change (short vs long) Fold-change (short vs long) (description) Candidates microRNAs from [3]
hsa-miR-210-3p 0.0010555 4.02696 Short up vs long x
hsa-miR-93-5p 0.00111034 3.3278 Short up vs long x
hsa-miR-221-3p 0.0029257 6.45867 Short up vs long x
hsa-miR-22-3p 0.00472295 1.61837 Short up vs long
hsa-miR-151-5p 0.00943964 2.21248 Short up vs long
hsa-miR-20a-5p 0.0102997 2.39401 Short up vs long x
hsa-miR-92a-3p 0.0141019 1.69546 Short up vs long x
hsa-miR-30e-5p 0.0196756 3.32221 Short up vs long x
hsa-miR-146b-5p 0.021048 2.52768 Short up vs long
hsa-miR-17-5p 0.0219565 3.21235 Short up vs long x
hsa-miR-20b-5p 0.0256082 6.73325 Short up vs long
hsa-miR-27b-3p 0.0295604 1.71494 Short up vs long
hsa-miR-30c-5p 0.0319141 2.51445 Short up vs long
hsa-miR-374a-5p 0.0386754 9.82208 Short up vs long
hsa-miR-95-3p 0.046397 11.7385 Short up vs long
Cluster 11: long survival microRNA p-Value(short vs long) Fold-change (short vs long) Fold-change (short vs long) (description)
hsa-miR-671-5p 0.00122393 −2.28734 Short down vs long
hsa-miR-188-5p 0.00362187 −1.97211 Short down vs long
hsa-miR-1469 0.00424181 −3.8781 Short down vs long x
hsa-miR-654-5p 0.00460829 −12.2823 Short down vs long
hsa-miR-622 0.00508603 −1.974 Short down vs long
hsa-miR-662 0.00675084 −7.14828 Short down vs long x
hsa-miR-1471 0.00688436 −3.04317 Short down vs long
hsa-miR-1183 0.00831059 −1.9464 Short down vs long
hsa-miR-431-5p 0.0100513 −5.19376 Short down vs long
hsa-miR-370-3p 0.0111777 −2.9025 Short down vs long
hsa-miR-345-5p 0.0122815 −6.13592 Short down vs long
hsa-miR-483-5p 0.012858 −1.80356 Short down vs long
hsa-miR-877-3p 0.0233915 −1.64644 Short down vs long
hsa-miR-1225-5p 0.025947 −1.56253 Short down vs long
hsa-miR-30c-1-3p 0.0262453 −4.46393 Short down vs long
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Fig. 3. Venn diagram showing common gene targets within hippo signaling, PI3K/Akt
signaling and focal adhesion pathways. The number denotes number of gene targets
(extracted from starBase v2.0) in common with a speciﬁc pathway. For example, CCND2,
target of hsa-miR-17-5p appears to be a common target to these three enriched
pathways. At a systems level, design of microRNA-based therapeutic agents can then be
deduced to either rescuing defective genes within a beneﬁcial pathway and/or shutting
down pathological gene(s) upstream of a regulatory cascade. For example; 1) YWHAG
(hsa-miR-222-3p) and CCND2 (hsa-miR-17-5p) are two genes that can be targeted to
modulate gene expression in both PI3K/Akt signaling and hippo signaling pathways; 2)
CCND2, AKT3, ITGA5, COL1A1 and ITGB8 can be targeted to affect PI3K/Akt signaling and
focal adhesion pathways and 3) CCND2, PPP1CB and PPP1CC can be targeted by hsa-miR-
17-5p, hsa-miR-23a-3p and hsa-miR-27a-3p respectively to modulate hippo signaling
and focal adhesion pathways.
47R.C.Y. Lin et al. / Genomics Data 9 (2016) 44–49characterize and compare the biological pathways best represented in
both series. The higher the enrichment score the more enriched the
genes are within a speciﬁc pathway (Table 2).
As shown from alternate data processing (Fig. 1) and discovery pro-
cesses (Fig. 2), the results from these additional analyses support the ro-
bustness of miR-Score outlined in Kirschner et al. [3]. In the ﬁrst
instance, the directionality of fold change of the candidate microRNAs
agrees (Table 1) where gene expression of hsa-miR-21-5p, hsa-miR-
221-3p and members of the hsa-miR-17-92 cluster (hsa-miR-17-5p,
hsa-miR-20a-5p) were higher in short survivors [3]. Furthermore,
these microRNAs have been shown by others to be involved in PTEN
regulation andmodulate the PI3K/Akt signaling pathway [20,21]. For vi-
sualization purposes, we compared genes targeted by these candidate
microRNAs from pathways that have been found to be associated with
cancer progression, tumor architecture and drug resistance [22,23],
i.e., PI3K/Akt signaling, hippo signaling and focal adhesion pathways
(Fig. 3, Table 3). All of which have been implicated in mesothelioma
biology [24].
2.3. Utilizing microRNA-based regulation to exert a systems effect
Of note, visualizing expression of microRNA and its targets within a
pathway and identifying commonalities between these pathways
(Fig. 3) enable further exploration, especially in terms of designing
microRNA therapeutic targets [25]. Complex disease conditions such
as heart failure and cancer are increasingly being recognized as the re-
sult of multiple dysfunctional pathways. Hence it is essential to change
our approach towards disease treatment and develop new therapeutic
strategies that seek to correct the overall network of pathways that
has been distorted. At a systems level, the aim of either rescuing defec-
tive genes within a beneﬁcial pathway and/or shutting down patholog-
ical gene(s) upstreamof a regulatory cascade becomes clearer using this
type of visualization approach [26–28]. For example, CCND2, a target of
hsa-miR-17-5p, appears to be common to the three enriched pathways
mentioned above. Inhibiting CCND2 expression via hsa-miR-17-5p
would thus modulate all three pathways and would have the potential
to reduce tumor growth. According to starBase [7], CCND2 is also a
target of hsa-miR-15/16 and thus can potentially be targeted by
TargomiRs, a novel microRNA-based treatment approach for MPM
using microRNA-loaded EGFR antibody-targeted minicells (EDV
™nanocells) [29]. In KEGG [19], CCND2 is shown to be deeply
entrenched in cell cycle progression, anti-apoptosis and pro-prolifera-
tion processes. Furthermore, in the case where gene expression of
hsa-miR-21-5p, hsa-miR-221-3p, hsa-miR-17-5p and hsa-miR-20a-5p
is higher in short survivors, an anti-microRNA approach [27] would be
appropriate to restore the suppressed beneﬁcial pathways.
In contrast, where down-regulated microRNAs are associated with a
disease condition, a re-introduction of these microRNAs can be utilized
to exert a systems effect in order to ameliorate dysregulated pathways.
For example, in MPM, miR-16, miR-15a and miR-15b mimics were ob-
served to have tumor suppressing properties [30] and subsequently aTable 2
Pathway enrichment analysis of predicted targets of short vs long candidate microRNAs (enric
Pathway name Enrichment score Enrich
Vasopressin-regulated water reabsorption 7.88895 0.000
Hippo signaling pathway 6.25988 0.001
Pancreatic cancer 5.794 0.003
Vascular smooth muscle contraction 5.71464 0.003
Chronic myeloid leukemia 5.57127 0.003
Hepatitis B 5.50279 0.004
Focal adhesion 5.47739 0.004
Dilated cardiomyopathy 5.46448 0.004
Regulation of actin cytoskeleton 5.43195 0.004
PI3K-Akt signaling pathway 5.03748 0.006
Shigellosis 4.84404 0.007
HTLV-I infection 4.74205 0.008mimic based on the consensus sequence of the miR-15 family has
shown signs of activity in a phase 1 clinical trial in MPM patients [29].
The assumption here is that detrimental pathways were rescued ge-
nome-wide. In comparison, a common seed-like sequence designed to
exert microRNA-like regulation at 3′UTR region of unrelated genes
[31,32] can also have a systems effect.
Using theMolecular Signatures Database (MSigDB, nowv5.1 [33]) to
apply Gene Set Enrichment Analysis (GSEA) to differentially expressed
genes from four MPM gene expression datasets, enabled us to identify
enriched microRNA binding motifs that can be translated into potential
druggable targets for MPM [34]. Here, GSEA on the twenty genes
(Table 3) extracted from the enriched pathways revealed promoter re-
gions (−2 kb, 2 kb) around transcription start sites containing enriched
binding motifs for transcriptional factors; MAZ (GGGAGGRR), PAX4
(GGGTGGRR), AP1 (TGANTCA) and FOXO4 (TTGTTT). All of which are
implicated in MPM biology [35–37]. Using ChIPBase database (curatedhed P b 0.001, extracted from starBase: http://starbase.sysu.edu.cn).
ment p-Value # genes in list, in pathway Pathway ID
374863 5 kegg_pathway_57
91147 8 kegg_pathway_96
04576 6 kegg_pathway_249
29734 7 kegg_pathway_118
80564 6 kegg_pathway_69
07539 8 kegg_pathway_89
18024 9 kegg_pathway_188
23454 6 kegg_pathway_263
37454 9 kegg_pathway_139
49008 12 kegg_pathway_262
87516 5 kegg_pathway_82
72078 10 kegg_pathway_190
Table 3
Gene targets of candidate microRNAs from PI3K/Akt signaling, hippo signaling and focal adhesion pathways (enriched P b 0.001, extracted from starBase: http://starbase.sysu.edu.cn).
PI3K-Akt signaling pathway
Gene targets RefSeq/Gene name microRNA Position
COL1A1 NM_000088//collagen, type I, alpha 1 hsa-let-7i-5p chr17:48262068-48262074[−]
ITGB8 NM_002214//integrin, beta 8 hsa-miR-106b-5p chr7:20449851-20449858[+]
RBL2 NM_005611//retinoblastoma-like 2 hsa-miR-106b-5p chr16:53524846-53524853[+]
CCND2 NM_001759//cyclin D2 hsa-miR-17-5p chr12:4410143-4410149[+]
CDKN1A NM_000389//cyclin-dependent kinase inhibitor 1A (p21, Cip1) hsa-miR-17-5p chr6:36654725-36654731[+]
JAK1 NM_002227//Janus kinase 1 hsa-miR-17-5p chr1:65298950-65298956[−]
EFNA3 NM_004952//ephrin-A3 hsa-miR-210-3p chr1:155059817-155059823[+]
YWHAG NM_012479//tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma hsa-miR-222-3p chr7:75956151-75956157[−]
ITGA5 NM_002205//integrin, alpha 5 (ﬁbronectin receptor, alpha polypeptide) hsa-miR-25-3p chr12:54789081-54789088[−]
CSF1 NM_000757//colony stimulating factor 1 (macrophage) hsa-miR-27a-3p chr1:110472264-110472271[+]
KITLG NM_000899//KIT ligand hsa-miR-27a-3p chr12:88890807-88890814[−]
AKT3 NM_001206729//v-akt murine thymoma viral oncogene homolog 3 hsa-miR-93-5p chr1:243667403-243667409[−]
Hippo signaling pathway
GDF6 NM_001001557//growth differentiation factor 6 hsa-let-7i-5p chr8:97154690-97154697[−]
TGFBR1 NM_001130916//transforming growth factor, beta receptor 1 hsa-let-7i-5p chr9:101911662-101911669[+]
CCND2 NM_001759//cyclin D2 hsa-miR-17-5p chr12:4410143-4410149[+]
FRMD6 NM_001042481//FERM domain containing 6 hsa-miR-20a-5p chr14:52194908-52194915[+]
TGFBR2 NM_001024847//transforming growth factor, beta receptor II (70/80 kDa) hsa-miR-21-5p chr3:30733297-30733303[+]
YWHAG NM_012479//tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma hsa-miR-222-3p chr7:75956151-75956157[−]
PPP1CB NM_002709//protein phosphatase 1, catalytic subunit, beta isozyme hsa-miR-23a-3p chr2:29022976-29022982[+]
PPP1CC NM_002710//protein phosphatase 1, catalytic subunit, gamma isozyme hsa-miR-27a-3p chr12:111158440-111158447[−]
Focal adhesion
COL1A1 NM_000088//collagen, type I, alpha 1 hsa-let-7i-5p chr17:48262068-48262074[−]
ITGB8 NM_002214//integrin, beta 8 hsa-miR-106b-5p chr7:20449851-20449858[+]
MAPK9 NM_002752//mitogen-activated protein kinase 9 hsa-miR-106b-5p chr5:179663017-179663023[−]
CCND2 NM_001759//cyclin D2 hsa-miR-17-5p chr12:4410143-4410149[+]
PPP1CB NM_002709//protein phosphatase 1, catalytic subunit, beta isozyme hsa-miR-23a-3p chr2:29022976-29022982[+]
ITGA5 NM_002205//integrin, alpha 5 (ﬁbronectin receptor, alpha polypeptide) hsa-miR-25-3p chr12:54789081-54789088[−]
PPP1CC NM_002710//protein phosphatase 1, catalytic subunit, gamma isozyme hsa-miR-27a-3p chr12:111158440-111158447[−]
VCL NM_003373//vinculin hsa-miR-34a-5p chr10:75878809-75878815[+]
AKT3 NM_001206729//v-akt murine thymoma viral oncogene homolog 3 hsa-miR-93-5p chr1:243667403-243667409[−]
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DNA sequencing data) [38], we characterized further how these tran-
scriptional factors interact with candidate microRNAs in the MPM sys-
tem. Here, we found that Jun./AP1 binds to the promoter region
(deﬁned by ChIPBase as 5 kb upstream and 1 kb downstream) of the
following microRNAs: hsa-miR-30c-1, hsa-miR-30e, hsa-miR-20a, hsa-
miR-19a, hsa-miR-19b-1, hsa-miR-17, hsa-miR-18a, hsa-miR-92a-1,
hsa-miR-93, hsa-miR-106b, hsa-miR-25, hsa-miR-210 and hsa-miR-
95. This analysis implicated that targets of the microRNAs identiﬁed in
our miR-Score study have the capacity to regulate other microRNAs
(see Ooi et al. [28] for in-depth discussion on microRNA-transcriptional
factor-microRNA interactions in a cardiovascular disease model [28]).
Thus, the approach to identify enriched binding motifs and biological
themes hasmerit in prioritizing genes for downstream validation, espe-
cially towards developing therapeutic agents. The complexity of the
microRNA-transcriptional factor interactions is inferred here and we
continue to utilize these approaches in our investigation into mesothe-
lioma pathology.
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